Novartis, Intercell Form Deal Worth Up To €67M

BioWorld International Correspondent

Intercell AG entered a marketing and distribution agreement with Novartis AG under which the latter company will sell its Japanese encephalitis virus (JEV) vaccine, IC51, in the U.S., Europe, Japan, Latin America and other selected territories.

To continue reading subscribe now to BioWorld Asia (formerly International)